PATENT CLAIM ANALYSIS

Application Number: 16237275
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-05
Patent Classification: ["514", "235200"]

Abstract:
A compound represented by general formula (I) has a strong Axl inhibitory activity by introducing a distinctive bicyclic structure in which a saturated carbon ring is fused to a pyridone ring, and can be a therapeutic agent for Axl-related diseases, for example, cancer such as acute myeloid leukemia, melanoma, breast cancer, pancreatic cancer, and glioma, kidney diseases, immune system diseases, and circulatory system diseases

Claim (Index 1):
A pharmaceutical composition comprising N-{5-[(6,7-dimethoxy-4-quinolinyl)oxy]-2-pyridinyl}-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydro-3-quinolinecarboxamide, or a salt thereof; and a pharmaceutically acceptable carrier.

Metadata:
- Claim Count in Document: 3.0
- Percentile: 98.0
- Lexical Diversity: 1.46154
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15373091', '14906993', '15975999', '15539530', '15034905']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8114282751579623
- 35 USC 102 Novelty (BERT): 0.588227257494999
- Combined Prediction Score: 0.789108173391666
- Mean Citation Score: 450.89663200000007
- Max Citation Score: 514.5780599999998
- Similarity Product: 431.70657116063103

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test